Login to Your Account

Adamas: Forest submits NDA for AD combo pill, PD therapy in the works

By Randy Osborne
Staff Writer

Tuesday, March 4, 2014
With a wholly owned drug for Parkinson’s disease (PD) at the phase III stage, Adamas Pharmaceuticals Inc. said Forest Laboratories Inc. – its partner for a combo Alzheimer’s disease (AD) therapy – submitted a new drug application (NDA) to the FDA for the once-daily capsule MDX-8704 to treat AD-related dementia.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription